Ultragenyx Pharmaceutical (RARE) Goodwill & Intangibles (2017 - 2026)

Ultragenyx Pharmaceutical (RARE) has 10 years of Goodwill & Intangibles data on file, last reported at $218.0 million in Q1 2026.

• On a quarterly basis, Goodwill & Intangibles fell 1.33% year-over-year to $218.0 million in Q1 2026; TTM through Mar 2026 was $218.0 million, a 1.33% decrease from a year earlier, with the FY2025 full-year figure at $220.0 million, down 0.9% from the prior year.
• Goodwill & Intangibles for Q1 2026 stood at $218.0 million, down from $220.0 million in the prior quarter.
• Over the last five years, Goodwill & Intangibles for RARE reached as high as $222.0 million in Q4 2024 and fell as low as $201.7 million in Q3 2023.
• Historically, Goodwill & Intangibles has averaged $211.1 million across 5 years, with a median of $209.5 million in 2024.
• Across the five-year window, Goodwill & Intangibles rose 16.73% in 2022 and declined 1.33% in 2026, its largest moves.
• Year by year, Goodwill & Intangibles stood at $204.5 million in 2022, then grew by 6.68% to $218.2 million in 2023, then gained by 1.75% to $222.0 million in 2024, then decreased by 0.9% to $220.0 million in 2025, then decreased by 0.91% to $218.0 million in 2026.
• Per Business Quant data, the three most recent Goodwill & Intangibles figures were $218.0 million in Q1 2026, $220.0 million in Q4 2025, and $217.3 million in Q3 2025.